Healthcare / Medical DevicesStockholm
$0.56
+0.08 (+16.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-18.1M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$90M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-38.8%
↓Gross Margin
16.2%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-4507.5%
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $401000.0 · net income $-14.6M · FCF $-18.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $401000.00 | $401000.00 | — | — | — |
| Net Income | $-14.6M | $-14.6M | $-12.7M | $-11.0M | $-11.3M |
| EBITDA | $-13.1M | $-13.1M | $-12.2M | $-10.6M | $-11.0M |
| EPS | -0.25 | -0.25 | -0.31 | -0.30 | -0.33 |
| Gross Margin | 16.2% | 16.2% | — | — | — |
| Operating Margin | -3658.4% | -3658.4% | — | — | — |
| Net Margin | -3643.4% | -3643.4% | — | — | — |
| Balance Sheet | |||||
| Current Ratio | 1.89 | 1.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.1M | $-18.1M | $-18.3M | $-15.1M | $-15.0M |
| Returns | |||||
| ROE | -38.8% | -38.8% | -44.8% | -35.1% | -35.5% |
| Valuation | |||||
| P/B | 0.86 | 0.86 | 4.46 | 3.58 | 6.02 |
| Growth & Yield | |||||
| EPS Growth | 17.8% | 17.8% | -2.3% | 8.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-81.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.31 → -0.25
Residual
-81.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.